Mostrar el registro sencillo del ítem

dc.contributor.authorRubio, M.J.
dc.contributor.authorLecumberri, M.J.
dc.contributor.authorVarela Ferreiro, Silvia 
dc.contributor.authorAlarcón, J.
dc.contributor.authorOrtega, M.E.
dc.contributor.authorGaba, L.
dc.contributor.authorEspinós, J.
dc.contributor.authorCalzas, J.
dc.contributor.authorBarretina, P.
dc.contributor.authorRuiz, I.
dc.contributor.authorMarquina, G.
dc.contributor.authorSantaballa, A.
dc.date.accessioned2022-05-23T08:38:18Z
dc.date.available2022-05-23T08:38:18Z
dc.date.issued2020
dc.identifier.issn2352-5789
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32566719es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16799
dc.description.abstractObjective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization. Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracycline-containing regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Results: Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5-7.3) and 18.5 months (95%CI: 11.5-25.6), respectively. Median OS was significantly higher (P = 0.028) in patients receiving trabectedin in </= 2nd line (25.3 months) than in >/= 3rd (15.1 months) and with ECOG performance status </= 1 at trabectedin start (19.8 months) than ECOG 2-3 (6.0 months, P = 0.013). When calculating OS since diagnosis, patients had longer OS with localized disease at diagnosis (87.4 months) vs. locally advanced (30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy (87.4 months) compared with those who did not (30.0 months, P = 0.003), especially when receiving radiochemotherapy (106.7 months, P = 0.027). One patient (2.8%) had a complete response (CR) and nine patients (25.0%) achieved a partial response (PR) for an objective response rate of 27.8% with median response duration of 11 months (range: 4-93). Eighteen patients (50.0%) had disease stabilization for a disease control rate (DCR) of 77.8%. More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in >/= 2nd line/s (0.0% and 20.0%), whereas the DCR was similar across treatment lines. Reversible neutropenia was the most common grade 3/4 laboratory abnormality (19.4%). Conclusions: Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure to an anthracycline-based regimen being comparable to those reported in clinical trials and with a manageable safety profile.en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleEfficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)en
dc.typeJournal Articlees
dc.authorsophosRubio, M.J.;Lecumberri, M.J.;Varela, S.;Alarcón, J.;Ortega, M.E.;Gaba, L.;Espinós, J.;Calzas, J.;Barretina, P.;Ruiz, I.;Marquina, G.;Santaballa, A.
dc.identifier.doi10.1016/j.gore.2020.100594
dc.identifier.pmid32566719
dc.identifier.sophos42921
dc.journal.titleGYNECOL ONCOLOGY REPORTSes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médicaes
dc.page.final100594es
dc.rights.accessRightsopenAccess
dc.subject.keywordHULAes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number33.es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International